The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Harvard Bioscience Inc (NASDAQ: HBIO) closed at $0.45 in the last session, down -4.94% from day before closing price of $0.48. In other words, the price has decreased by -$4.94 from its previous closing price. On the day, 0.67 million shares were traded. HBIO stock price reached its highest trading level at $0.4826 during the session, while it also had its lowest trading level at $0.45.
Ratios:
We take a closer look at HBIO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.59. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 2.75 whereas as Long-Term Debt/Eq ratio is at 0.45.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 21285464 and an Enterprise Value of 56159884. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.23 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 0.633 whereas that against EBITDA is 15.873.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.55, which has changed by -0.8426573 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $3.04, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -5.31%, while the 200-Day Moving Average is calculated to be -52.37%.
Shares Statistics:
According to the various share statistics, HBIO traded on average about 1.18M shares per day over the past 3-months and 526480 shares per day over the past 10 days. A total of 44.53M shares are outstanding, with a floating share count of 37.92M. Insiders hold about 14.85% of the company’s shares, while institutions hold 43.69% stake in the company. Shares short for HBIO as of 1755216000 were 592185 with a Short Ratio of 0.50, compared to 1752537600 on 1163912. Therefore, it implies a Short% of Shares Outstanding of 592185 and a Short% of Float of 1.4400001.
Earnings Estimates
The market rating of Harvard Bioscience Inc (HBIO) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.03 and $0.03 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.15 and $0.04.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $19M. It ranges from a high estimate of $19M to a low estimate of $19M. As of the current estimate, Harvard Bioscience Inc’s year-ago sales were $21.97MFor the next quarter, 1 analysts are estimating revenue of $22.8M. There is a high estimate of $22.8M for the next quarter, whereas the lowest estimate is $22.8M.
A total of 1 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $84M, while the lowest revenue estimate was $84M, resulting in an average revenue estimate of $84M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $91.6M in the next fiscal year. The high estimate is $95.8M and the low estimate is $87.4M.